✓ Translated by DotMD AI Clinical Council Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #36068705 ↗

Phase III Randomized Trial: Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

Original Paper Title: “Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin. Both formulations of sulopenem were well-tolerated.
Study Design & Sample: Phase III Randomized Trial published in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Multi-cohort synthesis).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. Key clinical takeaway: Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin. Both formulations of sulopenem were well-tolerated.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023-01-06; Phase III Randomized Trial; Rigor 82/100): Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin. Both formulations of sulopenem were well-tolerated.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: urinary-pain-relief-phenazopyridine-hydrochloride → Rx: ertapenem-sodium → Rx: ciprofloxacin → Rx: ciprofloxacin-hcl → Condition: otomycosis → Condition: neurosyphilis →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36068705: Phase III Randomized Trial: Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

3 of 3 Free Questions Remaining